

OCT 23 2003

SHEET 1 OF 1

Substitute for forms 1449A/PTO & 1449B/PTO		ATTORNEY'S Dkt No. 034008-027	APPLICATION NO. 09/010,377
FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT S.A. RUBIN et al.	
		FILING DATE January 21, 1998	GROUP 1644

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>RC</i>	ZEIDLER et al., "Therapeutic Effects of Antibodies Against Adhesion Molecules in Murine Collagen Type II-Induced Arthritis", <i>Autoimmunity</i> , 1995, pp. 245-252, vol. 21, Taylor & Francis Health Sciences, London, England
/	BLUE et al., "Enhancement of CD-2 Mediated T Cell Activation by the Interaction of VLA-4 with Fibronectin", <i>Cellular Immunology</i> , 1991, pp. 238-244, vol. 138, Academic Press, Orlando, Florida.
/	GARCIA-VICUÑA et al., "VLA family in rheumatoid arthritis: evidence for <i>in vivo</i> regulated adhesion of synovial fluid T cells to fibronectin," <i>Clinical and Experimental Immunology</i> , 1992, pp. 435-441, vol. 88, Blackwell Scientific Publications, Oxford, England.
/	ISSEKUTZ et al., "T Lymphocyte Migration to Arthritic Joints and Dermal Inflammation in the Rat: Differing Migration Patterns and the Involvement of VLA-4," <i>Clinical Immunology and Immunopathology</i> , 1991, pp. 436-447, vol. 61, Academic Press, Orlando, Florida.
/	ISSEKUTZ et al., "Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease," <i>Immunology</i> , 1996, pp. 569-576, vol. 88, Blackwell Science Ltd., Oxford, England.
/	ELICES et al., "Expression and Functional Significance of Alternatively Spliced CS1 Fibronectin in Rheumatoid Arthritis Microvasculature", <i>Journal of Clinical Investigation</i> , 1994, pp. 405-416, vol. 93, American Society for Clinical Investigation, New Haven, CT.
/	MIYAKE et al., "B1 Integrin-mediated Interaction with Extracellular Matrix Proteins Regulates Cytokine Gene Expression in Synovial Fluid Cells of Rheumatoid Arthritis Patients," <i>Journal of Experimental Medicine</i> , 1993, pp. 863-868, vol. 177, Rockefeller Univ. Press, New York, New York.
<i>M</i>	ISSEKUTZ et al., "Rat Blood Neutrophils Express Very Late Antigen 4 and It Mediates Migration to Arthritic Joint and Dermal Inflammation", <i>Journal of Experimental Medicine</i> , 1996, pp. 2175-2184, vol. 183, Rockefeller Univ. Press, New York, New York.

Examiner Signature	<i>P. Klein Gamma 11/26/03</i>	Date Considered
--------------------	--------------------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO		ATTORNEY'S DKT NO. 002010-746	APPLICATION NO. 09/010,377
SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT S. A. RUBIN et al.	FILING DATE January 21, 1998
		GROUP 1644	



**SECOND INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

MAY 28 2013

U.S. PATENT DOCUMENTS

(MM-DD-YYYY)
RECEIVED
JUN 02 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>PL</i>	Olivier J.P. Léger et al. "Humanization of a mouse antibody against human alpha-4 integrin: A potential therapeutic for the treatment of multiple sclerosis," Human Antibodies, vol. 8(1), pp. 3-16 (1997).
<i>PL</i>	Frank KOLBINGER et al., "Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies," Protein Engineering, vol. 6(8), pp. 971-980 (1993).

Examiner Signature	P. Hirsch, Esq. (S) 4/26/17	Date Considered	
--------------------	-----------------------------	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for forms 1449A/PTO & 1449B/PTO

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

O P T J C 108
SEP 1 1 2003
U. S. PATENT AND TRADEMARK OFFICEATTORNEY'S DKT NO.
002010-746APPLICATION NO.
09/010,377

APPLICANT

S.A. RUBEN et al.

FILING DATE

January 21, 1998

GPO
164

RECEIVED

SEP 16 2003

TECH CENTER 1600 (MMR/2003)

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
W	YEDNOCK et al., "Prevention of experimental autoimmune encephalomyelitis by antibodies against $\alpha 4 \beta 1$ integrin," Letters to Nature, vol. 356, pp. 63-66 (1992).
	James S. GROBER et al., "Monocyte-Endothelial Adhesion in Chronic Rheumatoid Arthritis," J. Clin. Invest. vol. 91, pp. 2609-2619 (1993)
	S. JALKANEN et al., "A Novel Endothelial Cell Molecule Mediating Lymphocyte Binding in Humans," Behring Inst. Mitt., No. 92, pp. 36-43 (1993).
	C. FISCHER et al., "Lymphocyte-Endothelial Interactions Inflamed Synovia: Involvement of Several Adhesion Molecules and Integrin Epitopes," Scand. J. Immunol. Vol. 38, pp. 158-166, (1993).
	Marko SALMI et al., "Dual Binding Capacity of Mucosal Immunoblasts to Mucosal and Synovial Endothelium in Humans: Dissection of the Molecular Mechanisms," J. Exp. Med., vol. 181, pp. 137-149 (1995)
	Bernhard HOLZMANN et al., "Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with an α Chain Homologous to Human VLA-4," Cell vol. 56, pp. 37-46 (1989).
	Andrew C. ISSEKUTZ et al., "Monocyte Migration to Arthritis in the Rat Utilizes both CD11/CD18 and Very Late Activation Antigen 4 Integrin Mechanisms," J. Exp. Med. vol. 181, pp. 1197-1203 (1995).
	Andrew C. ISSEKUTZ et al., "A Major Portion of Polymorphonuclear Leukocyte and T Lymphocyte Migration to Arthritic Joints in the Rat Is via LFA-1/MAC-1-Independent Mechanisms," Clinical Immunology and Immunopathology vol. 67, no. 3, pp. 257-263 (1993).
	Paul P. TAK, "Expression of Adhesion Molecules in Early Rheumatoid Synovial Tissue," Clinical Immunology and Immunopathology vol. 77, no. 3, pp. 236-242 (1995).
	Jo C W EDWARDS et al., "Vascular cell adhesion molecule 1 and $\alpha 4$ and $\beta 1$ integrins in lymphocyte aggregates in Sjögren's syndrome and rheumatoid arthritis," Annals of the Rheumatic Diseases vol. 52, pp. 806-811 (1993).
	ACHM van DINOTHER-JANSSEN et al., "Role of the CS1 adhesion motif of fibronectin in T cell adhesion to synovial membrane and peripheral lymph node endothelium," Annals of the Rheumatic Diseases vol. 52, pp. 672-676 (1993).
	Hitoshi ISHIKAWA et al., "Adhesion molecules in the lymphoid cell distribution in rheumatoid synovial membrane," Bulletin Hospital for Joint Diseases vol. 53, no. 2, pp. 23-28 (1993).
	Jeanette MORALES-DUCRET et al., "Vascular Cell Adhesion Molecule-1 Expression in Synovium and on Fibroblast-Like Synoviocytes," the Journal of Immunology vol. 194, no. 4, pp. 1424-1431 (1993).
	Christopher W. MARLOR et al., "Rapid Communication Expression of Vascular Cell Adhesion Molecule-1 in Fibroblastlike Synoviocytes After Stimulation with Tumor Necrosis Factor," American Journal of Pathology vol. 140(5) pp. 1055-1059 (1992).
	Antonio A. POSTIGO et al., "Increased Binding of Synovial T Lymphocytes from Rheumatoid Arthritis to Endothelial-Leukocyte Adhesion Molecule-1 (ELAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1)," J. Clin. Invest. vol. 89, pp. 1445-1452 (1992).
	Anna C.H.M. van DINOTHER-JANSSEN et al., "THE VLA-R/VCAM-1 PATHWAY IS INVOLVED IN LYMPHOCYTE ADHESION TO ENDOTHELIUM IN RHEUMATOID SYNOVIUM," The Journal of Immunology vol. 147, no. 12, pp. 4207-4210 (1991)
	Thomas B. ISSEKUTZ et al., "T Lymphocyte Migration to Arthritic Joints and Dermal Inflammation in the Rat: Differing Migration Patterns and the Involvement of VLA-4," Clinical Immunology and Immunopathology vol. 61, pp. 436-447 (1991)
	Armando LAFFON et al., "Unregulated Expression and Function of VLA-4 Fibronectin Receptors on Human activated T Cells in Rheumatoid Arthritis," J. Clin. Invest. vol. 88, pp. 546-552 (1991).
M	Thomas B. ISSEKUTZ et al., "Inhibition of In Vivo Lymphocyte Migration to Inflammation and Homing to Lymphoid Tissues by the TA-2 Monoclonal Antibody," vol. 147, no. 12, pp. 4178-4184 (1991).

Examiner Signature	P. Hennig 6/16/03	Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(05/03)